PFIZER
PharmaceuticalsPfizer Ltd.
In 1950, Pfizer came to India via a company named Dumex and its first production unit was being set up at Darukhanna in Mumbai. The Company manufactured products such as Isonex, Protinex, Becosules, and Corex. In 1960, it set up one more plant located at Thane, near Mumbai with the purpose of manufacturing and conducting product research. In 1965, the company entered into a license agreement with Pfizer Corporation for the use of Pfizer’s processes, and technical know-how, and more for manufacturing its current products. Later in the year 1992, Dumex was being amalgamated with the Pfizer.
In India, it instituted the first-ever Disease Management Programme - Healthy Heart in Cardio Vascular Disease (Chronic Stable Angina, Hypertension, and Dyslipidemia), along with the partnership with Apollo Hospital, Hyderabad as well as the Apollo Hospital, Chennai.
About six Pfizer brands featured among the Top 100 pharmaceutical brands in India, in which the two of Pfizer India's brands named as Corex (or Cough Formulation) and Becosules (or Multivitamin) - continued to rank among the Top 15 pharmaceutical drug brands.
Also, its manufacturing plant was ISO 14001 certified due to its Environment Management System and was awarded by DNV Certification B.V, Netherlands.
In 2013, both Pfizer Ltd and Wyeth Ltd agreed to merge and created a single Pfizer Brand.
Prescription Drugs:Under this segment, the company manufactured the prescribed drugs such as Citralka Liquid, Viagra, Dolonex Gel, Lyrica, Ponstan, and more.
- Trades at a P/E of 43.6, with a return on equity (ROE) of 16%.
- PFIZER is trading below all of its key moving averages (10/20/50/100/200-DMA) — a bearish technical setup.
- Year-to-date it is down 16.43%, and down 15.58% over the past year.
- At ₹4,060.20 it sits about 0% of the way up its 52-week range (₹4,054.00–₹5,578.50).
- Offers a dividend yield of 0.67%.
- Market capitalisation stands at ₹18,585 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Nov 2009 | ₹772 Cr | ₹137 Cr | ₹45.87 | 17.75% |
| Nov 2008 | ₹678 Cr | ₹300 Cr | ₹98.27 | 44.25% |
| Nov 2007 | ₹676 Cr | ₹340 Cr | ₹109.27 | 50.3% |
| Nov 2006 | ₹664 Cr | ₹106 Cr | ₹32.48 | 15.96% |
| Mar 2023 | ₹2,425 Cr | ₹624 Cr | ₹136.38 | 25.73% |
| Mar 2022 | ₹2,611 Cr | ₹613 Cr | ₹133.90 | 23.48% |
| Mar 2021 | ₹2,239 Cr | ₹498 Cr | ₹108.77 | 22.24% |
| Mar 2020 | ₹2,152 Cr | ₹509 Cr | ₹111.29 | 23.65% |
| Mar 2020 | ₹2,152 Cr | ₹509 Cr | ₹111.29 | 23.65% |
| Mar 2019 | ₹2,082 Cr | ₹429 Cr | ₹93.79 | 20.61% |
| Mar 2018 | ₹1,969 Cr | ₹360 Cr | ₹78.71 | 18.28% |
| Mar 2017 | ₹1,966 Cr | ₹337 Cr | ₹73.62 | 17.14% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 05 Dec 2007 | BIRLA SUNLIFE TRUSTEE CO PVT LTD AC INDIA EXCEL OFFSHORE FUND | SALE | 1,80,352 | ₹685.00 |
| 05 Dec 2007 | RELIANCE CAPITAL TRUSTEE CO LTD AC RELIANCE TAX SAVER FUND | PURCHASE | 2,00,215 | ₹685.00 |
| 13 Jul 2007 | FIDELITY TRUSTEE CO PVT LTD FIDELITY EQUITY FUND | SALE | 1,57,247 | ₹803.00 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.